Global Canine Oral Chewable Tablets Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

12/feb/2018 12:56:19 sai krishna Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Canine oral chewable tablets are the oral dosage form of medication with additives used to treat various types of canine diseases such as arthritis, canine congestive heart failure, tick and fleas infections, and among others. Various additives and flavouring agents are used in the formulation of canine oral chewable tablets for masking the unpleasant taste and odour of the drugs. The canine oral chewable tablets will dissolve in 2-5 minutes and the pharmacological action takes place immediately.

 

The global canine oral chewable tablets market is growing at a significant CAGR due to increase in the adoption of canines. Rise in the expenditure in animal welfare and wellness, wider availability of the canine oral chewable tablets in the market, and rise in the prevalence of various canine diseases such as tick and fleas infections, anticipated to fuel the canine oral chewable tablets market over the forecast period. In addition, ease of administration of tablets comparing with parenteral formulations, lack of nutrition values in the canine feed, and initiations taken by various pet organizations and NGOs for animal welfare are expected bolster the canine oral chewable tablets market over the forecast years. However, stringent regulatory policies for the approval of veterinary formulations, lack of awareness about the canine oral chewable tablets in rural areas, high cost of the products, and withdrawn of drugs from the market such as levothyroxine sodium due to FDA warning regarding the lack of approval might hinder the canine oral chewable tablets market growth in the coming future.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-canine-oral-chewable-tablets-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

The canine oral chewable tablets is segmented on the basis of composition type, drug class, product availability, and distribution channel

 

Based on the composition type, canine oral chewable tablets market is segmented into the following:

·        Botanically synthesized

·        Chemically synthesized

 

Based on the drug class, canine oral chewable tablets market is segmented into the following:

·        Analgesics

·        Anti-infective

·        Anti-ulcers

·        Vitamins & minerals

·        Cardiovascular drugs

·        Others

 

 

Based on the application, canine oral chewable tablets market is segmented into the following:

·        Gastrointestinal diseases

·        Cardiovascular disorders

·        Infectious diseases

·        Nutritional supplements

·        Others

 

 

Based on the product type, canine oral chewable tablets market is segmented into the following:

·        Prescription

·        Over the Counter (OTC)

 

Based on the distribution channel, canine oral chewable tablets is segmented into the following:

·        Veterinary clinics

·        Veterinary Pharmacies

·        Online veterinary stores

·        Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-canine-oral-chewable-tablets-market/#ulp-c654SbFYO64MsOhu

 

 

The global canine oral chewable tablets market is in the developing stage as several local and international players are actively engaged in the manufacturing of canine oral chewable tablets for the treatment of chronic canine diseases. Acquisitions and mergers, collaborations, joint ventures, and product launches, are some key strategies followed by the manufacturers for increasing their share in the canine oral chewable tablets market. For instance, in December 2015, Boehringer Ingelheim acquired Merial (Sanofi animal health) for strengthening its product portfolio. In addition, in May 2014, Merck Animal Health received the FDA approval for its drug Bravecto (fluralaner) used in the treatment of fleas and ticks infections. Moreover, in December 2014, Putney, Inc. launched the Carpofen canine oral chewable tablets for the treatment of pain and inflammation.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-canine-oral-chewable-tablets-market/#ulp-14mlyhjMGhVjZqa3

 

Geographically, canine oral chewable tablets market is segmented into the following regions Viz. Europe, Latin America, Asia Pacific, North America, and Middle East and Africa. North America holds a significant share in global canine oral chewable tablets owing to increase in the adoption of canines (according to American Pet Products Association, approximately 78 Mn canines were owned in the U.S.), rise in the awareness of canine’s health, growth in the expenditure on animal welfare, increase in the research and development activities for the innovation of new products for chronic canine diseases might fuel the canine oral chewable tablets market in the region. Asia Pacific accounts for key share, which is attributed to increase in the prevalence of various canine microbial diseases due to unhygienic conditions, rise in the expenditure on animal welfare, and diversification of business segment in Asia Pacific region by various manufacturers might bolster the canine oral chewable tablets market in Asia Pacific region. Europe holds a major share owing to increase in the awareness about pet’s health, rise in the prevalence of various canine diseases, lack of nutrition fortified canine feed, and rise in research and development activities for the canine oral chewable tablets market might propel the market growth in Europe region.

 

 

Some of the players in canine oral chewable tablets market are Zoetis, Inc. (Pfizer) (U.S), Virbac AH Inc. (France), Elanco (Eli Lilly and Co.) (U.S.), Boehringer Ingelheim vetmedica, Inc. (Boehringer Ingelheim) (Germany), Pala-Tech Laboratories (U.S.), Bayer HealthCare LLC, (Bayer AG) (Germany), Merck Animal Health (Merck &co. Inc.) (U.S.), and Putney, Inc. (Dechra Pharmaceuticals) (U.K.) to name a few.

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com

 

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl